Current issues of ACP Journal Club are published in Annals of Internal Medicine


Infliximab plus methotrexate was more effective than methotrexate alone in rheumatoid arthritis


ACP J Club. 2001 Jul-Aug;135:3. doi:10.7326/ACPJC-2001-135-1-003

Related Content in this Issue
• Companion Abstract and Commentary: Etanercept was more effective and safer than methotrexate in reducing disease progression in early rheumatoid arthritis

Source Citation

Lipsky PE, van der Heijde DM, St. Clair EW, et al., for the Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med. 2000 Nov 30;343:1594-602. 1096166



In patients with rheumatoid arthritis (RA), is infliximab combined with methotrexate (MTX) more effective than MTX alone?


Randomized {allocation concealed*}†, blinded (patients and outcome assessors),* placebo-controlled trial with follow-up at 54 weeks.


Academic rheumatology centers in the United States, Canada, and Europe.


428 patients (mean age 53 y, 52% men) who were receiving ≥ 12.5 mg/wk of MTX for treatment of active RA (defined as ≥ 6 swollen joints, ≥ 6 tender joints, and ≥ 2 of the following: morning stiffness ≥ 45 min, erythrocyte sedimentation rate ≥ 28 mm/h, or a serum C-reactive protein level of ≥ 2 mg/dL) participated in the study. Follow-up was 100%.


All patients continued MTX as previously prescribed and were initially allocated to 3 groups: infusion of placebo (n = 88), 3 mg/kg of body weight of infliximab (n = 172), or 10 mg/kg of infliximab (n = 168) to be received at 0, 2, and 6 weeks. The placebo group continued with placebo infusions every 4 weeks, and the groups receiving 3 or 10 mg/kg of infliximab were divided into subgroups receiving the same dose at 4 or 8-week intervals until week 54.

Main outcome measures

Disease activity (based on American College of Rheumatology [ACR] criteria), hand and foot joint erosion and narrowing (based on the Sharp scoring system modified by van der Heijde [range 0 to 440]), and adverse events.

Main results

Infliximab plus MTX reduced disease activity more than did MTX alone (Table). Mean increase in the joint erosion score was 0.5 in patients receiving any dose of infliximab plus MTX and 4 for patients receiving MTX alone (P < 0.001); mean increase in the joint-narrowing score was 0.4 and 2.9, respectively (P < 0.001). Adverse events, including serious infections, did not differ between the patients receiving MTX alone or in combination with infliximab.


In patients with rheumatoid arthritis, infliximab combined with methotrexate was more effective than methotrexate alone in reducing disease activity and slowing radiologic progression.

*See Glossary.

†Information provided by author.

Source of funding: Centocor.

For correspondence: Dr. P.E. Lipsky, National Institutes of Health, 9000 Rockville Pike, Building 10, Room 9N228, Bethesda, MD 20892-1820, USA. FAX 301-402-0012.

Table. Percentage of patients with rheumatoid arthritis receiving methotrexate who show reduced disease activity on placebo vs infliximab*

Percentage of improvement at 54 wk (ACR criteria) Placebo Infliximab
3 mg/kg every 8 wk 3 mg/kg every 4 wk 10 mg/kg every 8 wk 10 mg/kg every 4 wk
20 17% 42% 48% 59% 59%
50 8% 21%† 34% 39% 38%
70 2% 10%‡ 17% 25% 19%

*ACR = American College of Rheumatology. All comparisons vs placebo are P < 0.001 unless otherwise specified.
P = 0.027.
P = 0.04.


The central role of tumor necrosis factor (TNF) in perpetuating synovial inflammation in RA has been convincingly shown in clinical trials of 2 biological agents that inhibit TNF. Etanercept is a fusion protein that competes with the TNF receptor, and infliximab is a monoclonal antibody against TNF itself (1). After the apparent early success of TNF inhibitors, interest has moved to more specific questions about the place of these agents in the treatment of RA: Are they superior to conventional drugs? At what stage should they be introduced? Do they fundamentally alter the course of the disease by suppressing joint damage? Are they safe? Are they affordable? Which of these agents is preferable?

The sophisticated trials reported by Bathon and colleagues and by Lipsky and colleagues explore these issues. Bathon and colleagues compared the efficacy of etanercept and MTX (now the standard disease-modifying drug) in early RA (defined as disease not exceeding 3 years' duration). Although other disease-modifying drugs were stopped, about 40% of patients continued to receive steroids. Etanercept, used in a twice-weekly subcutaneous dose of 25 mg, controlled disease activity more rapidly than did MTX in the first 6 months of treatment.

Although little difference existed in disease activity after 12 months of treatment, radiographic analysis showed that etanercept in this dose slowed the rate of bone erosion more effectively than did MTX over the 12-month trial period. Etanercept, used in a lower dose of 10 mg, induced a lower incidence of significant improvement at 12 months than did MTX and was no more effective in slowing joint erosion. A reaction at the injection site was the most troublesome adverse event from etanercept.

Lipsky and colleagues examined the effects of infliximab in patients with well-established RA (mean duration > 10 y) that was resistant to other drug treatment. All patients continued to receive MTX but not other disease-modifying drugs. The effects of different dose schedules of infliximab were compared with placebo infusions over a 54-week observation period. Infliximab in all doses reduced disease activity and improved function more effectively than did MTX alone. Furthermore, infliximab in all doses prevented further joint destruction even in patients in whom this process was already advanced. The incidence of the adverse event of immediate concern, namely serious infection, was not increased in infliximab-treated patients. Antibodies to double-stranded DNA were provoked in about 10% of patients.

These studies show that TNF inhibitors suppress disease activity in some patients with RA. Their superior ability to slow or possibly reverse joint erosion in advanced disease over a 12-month period has also been shown. However, the latter point has not been established in patients with early disease because of the possible confounding effect of concomitant steroid treatment (2). Only 50% of patients treated with etanercept at an early stage of disease and 27% of patients treated with infliximab at a late stage of disease had a 50% reduction in disease activity. No guidelines as yet exist to select likely responders. Furthermore, an observation period of 1 year is too short to judge either the long-term clinical and radiologic effects of these biologic agents or their propensity for causing side effects. Although the appearance of antibodies to double-stranded DNA has little clinical significance in the short term (3), longer-term observation is necessary. Frequent subcutaneous injections of etanercept can be self-administered, but the high incidence of local reactions raises practical and medicolegal concerns. However, these reactions were rarely bothersome enough to stop treatment. Intravenous infliximab is unlikely to be self-administered and is given relatively infrequently.

On current evidence, rheumatologists are unlikely to resort to infliximab or etanercept in early RA and will reserve their use for selected patients resistant to other treatment.

A. Michael Denman, MD
Northwick Park NHS Trust Hospital
Middlesex, England, UK


1. Maini RN, Taylor PC. Anti-cytokine therapy for rheumatoid arthritis. Annu Rev Med. 2000;51:207-29.

2. Hickling P, Jacoby RK, Kirwan JR, and the Arthritis and Rheumatism Council Low Dose Glucocorticoid Study Group. Joint destruction after glucocorticoids are withdrawn in early rheumatoid arthritis. Br J Rheumatol. 1998;37:930-6.

3. Charles PJ, Smeenk RJ, De Jong J, Feldmann M, Maini RN. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum. 2000;43:2383-90.